AUSTIN, TEX.– Genetic testing holds promise for guiding the prescribing of antiplatelet therapies, particularly clopidogrel, but “we’re not there yet,” according to Dr. Steven Hollenberg, director of the coronary care unit at Cooper University Hospital in Camden, N.J.Genetic testing for clopidogrel responsiveness “certainly makes good sense, but I think we’re going to have to wait for good data” that better informs clinical decision making.Dr. Hollenberg discussed the implications of the negative results of the ARCTIC trial, which showed platelet function testing with antiplatelet therapy adjustment failed to improve clinical outcomes compared with standard unmonitored thienopyridine therapy in elective PCI. He also analyzed the results of other studies relevant to optimal antiplatelet and anticoagulant therapy, including the surprising outcomes of the WOEST trial.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.
On Twitter @whitneymcknight